Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Inclusion Criteria

• •Histologically confirmed adenocarcinoma of the prostate
• •Recurrent prostate cancer following primary therapy as defined by:
• •* Post-radical prostatectomy: Any PSA \>= 0.4 ng/ml
• •* Post-primary radiotherapy: PSA \>= 2 ng/ml above a post-radiotherapy nadir
• •* Post-primary androgen-deprivation therapy: A confirmed rise of PSA \>= 2 ng/ml above a post-therapy nadir
• •For patients with non-castrate levels of circulating androgen levels (testosterone \>= 50 g/dl)
• •* PSA levels should be increasing on at least two occasions \>= 1 week apart
• •* Patients should not be considered candidates for radiation therapy
• •For patients with castrate levels of circulating androgen levels (testosterone \< 50 ng/dl):
• •* PSA levels must be \>= 0.4 ng/ml (if history of radical prostatectomy) or \>= 2 ng/ml (if history of non-surgical primary treatment) and found to be increasing on at least two occasions \>= 1 week apart
• •At least 4 weeks must have elapsed since any changes to hormonal therapy, including at least 4 weeks since flutamide and at least 6 weeks since bicalutamide, nilutamide, or enzalutamide
• •No evidence of metastatic cancer on imaging including a bone scan and computed tomography (CT) scan of chest/abdomen/pelvis
• •Able to understand and adhere to dietary and medication restrictions as recommended for the safe use of phenelzine
• •Men with child bearing potential are required to use an effective means of contraception
• •Leukocytes \>= 3,000/mcL
• •Absolute neutrophil count \>= 1,500/mcL
• •Platelets \>= 100,000/mcL
• •Total bilirubin =\< 1.5 x upper limit of normal (ULN) except in cases of benign isolated hyperbilirubinemia such as Gilbert's syndrome.
• •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SPGT\]) =\< 2.5 x ULN
• •Creatinine =\< 1.5 x ULN